临床试验
适应性设计
样本量测定
序贯分析
计算机科学
医学物理学
资源(消歧)
贝叶斯概率
研究设计
增加物
管理科学
数据监测委员会
风险分析(工程)
临床研究设计
数据科学
样品(材料)
医学
数据挖掘
运筹学
监管科学
梅德林
软件
概率逻辑
随机对照试验
临床研究
作者
Christopher Jennison,Bruce W. Turnbull
标识
DOI:10.1201/9781584888482
摘要
In clinical trials, monitoring accumulating data at regular intervals is essential for balancing ethical and financial considerations against scientific rigor. This comprehensive second edition reflects the remarkable evolution in adaptive clinical trial methodology over the past two decades. Since publication of the first edition, these approaches have transformed from theoretical concepts to widely accepted practices, now endorsed by regulatory authorities, including formal FDA guidance. Features: Eleven entirely new chapters, including optimal design construction, delayed "pipeline" data accommodation, and multiple comparison procedures Eight dedicated chapters on adaptive methods including sample size re-assessment, seamless Phase II/III trials, multi-arm multi-stage trials, and enrichment designs Exact methods for binary and Poisson data with applications to vaccine trials Expanded discussion of binding versus non-binding futility boundaries for enhanced decision-making A chapter with a thoroughly updated review of Bayesian approaches to sequential trial design and analysis Incorporates response-adaptive treatment assignment in group sequential designs Practical computational methods and software guidance for implementing the techniques This definitive resource serves statisticians, clinical researchers, pharmaceutical scientists, and regulatory professionals involved in clinical trial design and analysis. The text balances theoretical foundations with practical implementation guidance, making it invaluable for both experienced practitioners and those new to adaptive trial methodology. With twice the content of the first edition, this volume provides the comprehensive understanding needed to design more efficient, ethical, and scientifically rigorous clinical trials, ultimately accelerating the delivery of effective treatments to patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI